

Press release from Emotra AB (publ)

Göteborg, November 1, 2018

## EMOTRA AB: Resolution on a new rights issue of shares for continued market introduction of EDOR®

**Today, November 1, 2018, EMOTRA AB (“Emotra”) announced that its Board of Directors have decided on a new rights issue of shares. This rights issue will comprise a maximum of 23,978,953 shares and the public has also been invited to participate. If fully subscribed, this new share issue will provide Emotra with a cash injection of appr. 19.2 MSEK before issue expenses. The Company has already received written commitments for approximately 10.15 MSEK, or about 53 per cent of the issue amount. This new share issue was decided with reference to a resolution passed at the annual shareholder meeting held on May 9, 2018. The resolution granted the Board the authority to carry out a new rights issue in order to raise more working capital to finance the continued market introduction of the Company’s EDOR® method.**

### **Daniel Poté, our CEO, says:**

*“At the beginning of 2018 Emotra decided to implement a new marketing strategy focusing on privately-run psychiatric hospitals and hospital chains in some of Europe’s largest metropolitan areas. This new strategy has shown promising commercialisation opportunities for EDOR®, especially as a number of blind clinical studies, most recently a study that is based on compounding the results from earlier studies, has provided clinical proof that hyporeactivity is a strong biomarker for suicide risk. So far, hyporeactivity is the only clear biomarker that has been demonstrated and it provides an excellent complement to the psychologically and socially conditioned risk factors that can be examined via traditional clinical interviews. The fact that we have been able to demonstrate the significance of hyporeactivity and that we can present EDOR as a reliable and objective complement to traditional examinations will make the decision for psychiatric clinics to implement the test in their regular practice so much easier.*

*The completion of our open, naturalistic, field study, EUDOR-A, also showed that the method works in comprehensive, routine clinical use. More than 1,500 patients at 16 clinics in 9 European countries were tested, and the result was a drastically reduced suicide rate compared with previous studies. In order to reap the full market potential and commercial opportunities of the EDOR® method, we plan on raising a maximum of 19.2 MSEK through a new rights issue of shares. This new capital will allow us to continue our market launch strategy of working major metropolitan areas with a high density of privately run psychiatric clinics, hospitals and hospital chains. We have already established that there is an interest in implementing new methods that can alleviate the problem of suicide, and the way these clinics operate allows them to charge for the tests they offer. Our goal is to have achieved a broad market acceptance among prominent psychiatric clinics in the Western world within two to three years.*

### **Rights issue to continue our market introduction of EDOR®**

Emotra will issue new shares to raise a total of appr. 19.2 MSEK. The funds from this rights issue will primarily be used to finance our continued marketing efforts and the establishment of a marketing organisation with the principal task of commercialising EDOR®. Emotra also intends to dedicate some of the funds to continued development of our product’s hardware and software, as well as to continued research in order to secure the Company’s position at the forefront of this area.

### **The offering in summary**

- **Subscription period:** November 12–19, 2018.
- **Subscription price:** SEK 0.80 per share
- **Record day:** November 8, 2018. The final day for trading in the company’s shares including the right to obtain subscription rights is November 6, 2018, and the first day without subscription rights is November 7, 2018
- **Preferential right:** Shareholders whose Emotra shares are registered on November 8, 2018 will have right of priority in the new share issue. Each outstanding share entitles the owner to one (1) subscription right. Four (4) subscription rights allow the shareholder to subscribe to seven (7) new shares. Please note that this new share issue is also open to the general public.

- **Issue volume:** The offering comprises a maximum of 23,978,953 new shares. If fully subscribed, this new share issue will provide the Company with a cash injection of 19,183,162.40 SEK before issue expenses.
- **Number of shares outstanding before the new issue:** 13,702,259.
- **Value (pre-money):** Approximately 11 MSEK.
- **Trading in subscription rights:** Trading in subscription rights will be carried out on Spotlight Stock Market from November 12 to November 27, 2018.
- **Trading in PSS:** Trading in PSS (Paid Subscribed Shares) will be carried out on Spotlight Stock Market from November 12, 2018, until the new share issue has been registered at Bolagsverket (The Swedish Companies Registration Office). We expect this registration to be completed at the end of December.
- **Guarantee:** Emotra has received subscription commitments for a total of 10.15 MSEK, which equals approximately 53% of the total issue value.
- **Market place:** Emotra's share is listed on Spotlight Stock Market.
- **ISIN code:** SE0006851507

Memorandum (including complete terms and instructions and further information about subscription commitments) as well as a teaser and subscription form without right of priority will be available on the company's web site ([www.emotra.se](http://www.emotra.se)), Göteborg Corporate Finances' (GCF) web site ([www.gcf.se](http://www.gcf.se)) and Spotlight Stock Market's web site ([www.spotlightstockmarket.se](http://www.spotlightstockmarket.se)) no later than the commencement of the subscription period.

#### Investor meetings

Aktiespararna, Stora Aktiedagen Göteborg, November 12, 2018, Svenska Mässan

Aktiespararna, Stora Aktiedagen Stockholm, November 26, 2018, Sheraton Hotel

To attend, please register at [www.aktiespararna.se](http://www.aktiespararna.se).

#### Financial Advisor

Emotra's Financial Advisor in connection with the planned rights issue is Göteborg Corporate Finance (GCF)

#### For further information about the planned rights issue, please contact:

Göteborg Corporate Finance

Telephone: +46 31 13 82 30

E-mail: [info@gcf.se](mailto:info@gcf.se)

#### For further information about Emotra, please contact:

Daniel Poté, CEO, telephone: +46 732 34 41 93, E-mail: [daniel@emotra.se](mailto:daniel@emotra.se)

Claes Holmberg, Chairman of the Board, telephone: +46 708 25 45 47, E-mail: [claes@emotra.se](mailto:claes@emotra.se)

*This information is the type of information that Emotra AB is legally obliged to publish in accordance with the EU market abuse regulation. This information was submitted for publication on November 1, 2018 under the above contact's supervision.*

---

**EMOTRA AB (publ)** is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR<sup>®</sup>, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

EMOTRA AB (publ), Göteborgsvägen 88, SE-433 63 Sävedalen, Sweden  
Tel: +46 708 25 45 47, [www.emotra.se](http://www.emotra.se)